HEK293 Expressed Full Length CD20 Protein
CD20 is a hot target for the treatment of lymphoma, leukemia and some autoimmune diseases. However, due to low expression titer and the unstable bioactivity, it is so difficult to find an active CD20 protein on the market for antibody drug development and the CD20 CAR expression detection.
ACROBiosystems has developed the highly active full length multi-transmembrane CD20 proteins, expressed by HEK293 cells. The active full length CD20 proteins carry both big and small ECD loops, and bind Rituximab and Ofatumumab with high binding affinity in ELISA and SPR assay. We have different types of CD20 proteins include unconjugated protein, biotinylated proteins with DDM and Nanodisc, which are suitable for immunization, ELISA, SPR, BLI and FACS.